H.C. Wainwright says the firm was not surprised that the independent data monitoring committee recommended that Rezolute’s (RZLT) sunRIZE trial continue as planned with no need to increase sample after DMC completed an interim analysis. The interim analysis was intended to evaluate for study futility or otherwise to inform a potential sample size increase. The recommendation offers a measure of validation for Rezolute’s assumption for the powering of the study, Wainwright adds. The firm has a Buy rating on the shares with a price target of $14.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RZLT:
- Rezolute Announces Pricing of Direct Stock Offering
- Rezolute’s Promising Clinical Developments and Positive Outlook: A Buy Recommendation by Yun Zhong
- Rezolute Receives Positive DMC Recommendation for Phase 3 Study
- Rezolute prices 20.79M shares at $3.25 in underwritten offering
- Rezolute announces DMC recommendation to continue Phase 3 sunRIZE study